Holen Sie sich die Stockscreener-App
106.92
5.08%
-5.72
Dianthus Therapeutics Inc Aktie (DNTH) Neueste Nachrichten
Dianthus Therapeutics, Inc. $DNTH Shares Bought by SummitTX Capital L.P. - MarketBeat
Octagon Capital Advisors LP Has $163.36 Million Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics Inc (DNTH) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dianthus Therapeutics Inc (DNTH) Cash Flow - TradingKey
Dianthus Therapeutics Inc (DNTH) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Dianthus Therapeutics, Inc. Revenue Breakdown – NASDAQ:DNTH - TradingView
Dianthus Therapeutics, Inc. Revenue Breakdown – BOATS:DNTH - TradingView
Spruce Street Capital LP Raises Stock Holdings in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Average Rating of "Moderate Buy" from Analysts - MarketBeat
DNTH|Dianthus Therapeutics Inc|Price:103.870|Chg%:-0.920 - TradingKey
Walleye Capital LLC Has $12.89 Million Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Jennison Associates LLC Buys New Position in Dianthus Therapeutics, Inc. $DNTH - MarketBeat
Dianthus Therapeutics (NASDAQ:DNTH) Sets New 52-Week HighTime to Buy? - MarketBeat
Dianthus Therapeutics Inc. Q1 2026 Earnings: Narrower-Than-Expected Loss Highlights Operational DisciplineProfit Announcement - dars.gov.et
Wedbush Maintains Dianthus Therapeutics (DNTH) Outperform Recommendation - MSN
Dianthus Therapeutics Stock Surges After Initiating Major Phase 3 Clinical Trial - TIKR.com
Enterprise value to EBITDA forward of Dianthus Therapeutics, Inc. – FWB:87E - TradingView
Dianthus Therapeutics, Inc. (DNTH) reports Q1 loss, lags revenue estimates - MSN
Dianthus Therapeutics DNTH Jumps As Phase 3 EMERGE Trial Kicks Off - timothysykes.com
DNTH Stock Pops As Phase 3 EMERGE Trial Kicks Off - StocksToTrade
Dianthus Therapeutics stock hits 52-week high at 102.38 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics stock hits 52-week high at 102.38 USD - Investing.com India
Dianthus Therapeutics Rockets As Phase 3 Hype Builds - TipRanks
Form 4 Dianthus Therapeutics Inc For: 13 July By Investing.com - Investing.com Nigeria
Dianthus therapeutics CFO Ryan Savitz sells $3.16 million in shares By Investing.com - Investing.com Australia
Dianthus therapeutics CFO Ryan Savitz sells $3.16 million in shares - Investing.com
Dianthus Therapeutics (DNTH) CFO sells 31,249 shares in 10b5-1 trades - Stock Titan
Dianthus Therapeutics (DNTH) Q1 2026 Earnings: Narrower-Than-Expected Loss Drives Positive SentimentMid-Term Outlook - Bölüm Sonu Canavarı
Dianthus Therapeutics (DNTH) Starts Phase 3 EMERGE Trial, Is The Upside Already Priced In? - Sahm
Form 144 Dianthus Therapeutics For: 9 July By Investing.com - Investing.com South Africa
[144] Dianthus Therapeutics, Inc. /DE/ SEC Filing - Stock Titan
Dianthus Therapeutics stock hits 52-week high at 99.36 USD By Investing.com - Investing.com Nigeria
Dianthus Therapeutics stock hits 52-week high at 99.36 USD - Investing.com
Dianthus Advances Claseprubart Into Phase 3 EMERGE Trial, Raising Stakes in the Myasthenia Gravis Market - TipRanks
Price to earnings forward of Dianthus Therapeutics, Inc. – MUN:87E - TradingView
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Enterprise value to revenue forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
DNTHDianthus Therapeutics Inc Revenue Breakdown - Finviz
Dianthus Therapeutics Inc. Q1 2026 Earnings: EPS Surprise of 22.28% Drives Positive Stock ReactionRevenue Per Share - dars.gov.et
DNTH News | DIANTHUS THERAPEUTICS INC (NASDAQ:DNTH) - ChartMill
Dianthus Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(C)(4) - The Manila Times
Cartesian Therapeutics Announces New Employment Inducement Grants - Yahoo Finance
Price to book forward of Dianthus Therapeutics, Inc. – NASDAQ:DNTH - TradingView
DNTH Stock Soars After Early ‘Go’ Decision For Drug In Autoimmune Disorder Program, Boosting Wall Street Optimism For Potential Launch - Stocktwits
Why Dianthus Therapeutics (DNTH) Is Up 11.4% After Launching Its Phase 3 EMERGE gMG Trial - Sahm
Dianthus Therapeutics stock hits 52-week high at 96.85 USD By Investing.com - Investing.com South Africa
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Dianthus Therapeutics, Inc.(NasdaqCM:DNTH) dropped from Russell 2000 Value Benchmark - marketscreener.com
2.44%
0.02%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):